VE303 定型细菌联合体预防复发性艰难梭菌感染:一项随机临床试验
这项2期随机双盲安慰剂对照剂量探索试验纳入79名高复发风险的艰难梭菌感染成人,比较VE303高剂量(8.0×10^9 CFU)、低剂量(1.6×10^9 CFU)与安慰剂口服14天。第8周复发率(分析定义3)高剂量组13.8%(4/29)、低剂量组37.0%(10/27)、安慰剂组45.5%(10/22),高剂量VE303 vs 安慰剂 P=.006。结论认为高剂量VE303可预防复发性CDI,需更大规模3期研究确认。
要点
- 高剂量VE303(8.0×10^9 CFU)每日口服14天,第8周CDI复发率13.8%(4/29) vs 安慰剂45.5%(10/22),P=.006。
- 低剂量VE303(1.6×10^9 CFU)第8周复发率37.0%(10/27) vs 安慰剂45.5%(10/22)。
- 研究为2期剂量探索试验,需更大规模3期研究确认高剂量VE303的预防作用。
核心结论
- 在实验室确诊CDI且近6个月有1次或以上既往CDI发作的成人以及高复发风险的原发性CDI成人中,高剂量VE303与安慰剂相比可预防复发性CDI。
- 需要更大规模的3期研究来确认这些发现。
研究设计与样本
- 2期、随机、双盲、安慰剂对照、剂量探索研究,于2019年2月至2021年9月在美国和加拿大的27个中心开展。
- 纳入79名18岁及以上、实验室确诊CDI且近6个月有1次或以上既往CDI发作的参与者,以及高复发风险的原发性CDI参与者(定义为≥75岁,或≥65岁且伴≥1项危险因素:肌酐清除率<60 mL/min/1.73 m2、使用质子泵抑制剂、远端[>6个月前]CDI病史)。
- 参与者随机分配至高剂量VE303(8.0×10^9菌落形成单位[CFU],n=30)、低剂量VE303(1.6×10^9 CFU,n=27)或安慰剂胶囊(n=22),每日口服一次,共14天。
主要发现
- 第8周CDI复发率(采用分析定义3)高剂量VE303组为13.8%(4/29),低剂量VE303组为37.0%(10/27),安慰剂组为45.5%(10/22)(高剂量VE303 vs 安慰剂 P=.006)。
- 基线特征在各组间相似:高剂量VE303组(n=29;另有1名参与者被排除在疗效分析之外)、低剂量VE303组(n=27)和安慰剂组(n=22)。
- 参与者中位年龄63.5岁(范围24-96);70.5%为女性;1.3%为亚洲人,1.3%为黑人,2.6%为西班牙裔,96.2%为白人。
关键数值与推荐
- 主要疗效终点为第8周时使用联合临床和实验室定义确定的CDI复发参与者比例。
- 主要疗效终点采用3种预设分析,对研究期间CDI复发采用 successively 更宽泛的定义:(1)符合CDI的腹泻加毒素阳性粪便样本;(2)符合CDI的腹泻加毒素阳性、聚合酶链反应阳性或产毒培养阳性的粪便样本;(3)符合CDI的腹泻加实验室确认,或(无粪便样本时)接受CDI靶向抗生素治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大规模的3期研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown. OBJECTIVE: To determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged ≥75 years or ≥65 years with ≥1 risk factors: creatinine clearance <60 mL/min/1.73 m2, proton pump inhibitor use, remote [>6 months earlier] CDI history). INTERVENTIONS: Participants were randomly assigned to high-dose VE303 (8.0 × 109 colony-forming units [CFUs]) (n = 30), low-dose VE303 (1.6 × 109 CFUs) (n = 27), or placebo capsules (n = 22) orally once daily for 14 days. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction-positive, or toxigenic culture-positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic. RESULTS: Baseline characteristics were similar across the high-dose VE303 (n = 29; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n = 27), and placebo (n = 22) groups. The participants' median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4/29) for high-dose VE303, 37.0% (10/27) for low-dose VE303, and 45.5% (10/22) for placebo (P = .006, high-dose VE303 vs placebo). CONCLUSIONS AND RELEVANCE: Among adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03788434.
引用
- Louie T, Golan Y, Khanna S, et al. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA. 2023. PMID: 37060545. doi:10.1001/jama.2023.4314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。